Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 378

Similar articles for PubMed (Select 19479125)

1.

Onychophagia as a spectrum of obsessive-compulsive disorder.

Pacan P, Grzesiak M, Reich A, Szepietowski JC.

Acta Derm Venereol. 2009;89(3):278-80. doi: 10.2340/00015555-0646.

2.

A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting).

Leonard HL, Lenane MC, Swedo SE, Rettew DC, Rapoport JL.

Arch Gen Psychiatry. 1991 Sep;48(9):821-7.

PMID:
1929772
3.

Sertraline: new indication. May help children with obsessive-compulsive disorder.

[No authors listed]

Prescrire Int. 2002 Jun;11(59):69-72.

PMID:
12068839
4.

Onychophagia and onychotillomania: prevalence, clinical picture and comorbidities.

Pacan P, Grzesiak M, Reich A, Kantorska-Janiec M, Szepietowski JC.

Acta Derm Venereol. 2014 Jan;94(1):67-71. doi: 10.2340/00015555-1616.

5.

Dermatology and conditions related to obsessive-compulsive disorder.

Stein DJ, Hollander E.

J Am Acad Dermatol. 1992 Feb;26(2 Pt 1):237-42. Review.

PMID:
1552059
6.

Sertraline and obsessive compulsive disorder: new indication. Limited assessment.

[No authors listed]

Prescrire Int. 2000 Aug;9(48):112-3.

PMID:
11067720
7.

Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.

[No authors listed]

Prescrire Int. 2004 Oct;13(73):163-5.

PMID:
15499694
8.

Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.

Ulloa RE, Nicolini H, Avila M, Fernández-Guasti A.

J Child Adolesc Psychopharmacol. 2007 Feb;17(1):85-96.

PMID:
17343556
9.

[Obsessive-compulsive symptoms in children and pre-adolescents: clinical observation of inpatients].

Minami T.

Seishin Shinkeigaku Zasshi. 1998;100(2):92-112. Japanese.

PMID:
9584573
10.

Psychopharmacology of pediatric obsessive-compulsive disorder: three case reports.

Oner O, Oner P.

J Psychopharmacol. 2008 Sep;22(7):809-11. doi: 10.1177/0269881107083362. Epub 2008 Feb 28.

PMID:
18308783
11.

Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.

Masi G, Millepiedi S, Perugi G, Pfanner C, Berloffa S, Pari C, Mucci M.

CNS Drugs. 2009;23(3):241-52. doi: 10.2165/00023210-200923030-00005.

PMID:
19320532
12.

Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.

Denys D.

Psychiatr Clin North Am. 2006 Jun;29(2):553-84, xi. Review.

PMID:
16650723
13.

[The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder].

Borkowska A, Pilaczyńska E, Araszkiewicz A, Rybakowski J.

Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):289-95. Polish.

PMID:
12647451
14.

Effects of sertraline on kinematic aspects of hand movements in patients with obsessive-compulsive disorder.

Mergl R, Mavrogiorgou P, Juckel G, Zaudig M, Hegerl U.

Psychopharmacology (Berl). 2004 Jan;171(2):179-85. Epub 2003 Aug 30.

PMID:
12955289
15.

Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.

Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ.

Int Clin Psychopharmacol. 2007 Nov;22(6):313-22. Review.

PMID:
17917549
16.

[Treatment of comorbid obsessive-compulsive and depressive disorders in children age].

Goriunov AV, Lobacheva MV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(11 Pt 2):48-52. Russian.

PMID:
23257756
17.

A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder.

Crockett BA, Churchill E, Davidson JR.

Ann Clin Psychiatry. 2004 Jul-Sep;16(3):127-32.

PMID:
15517844
18.

The self-mutilative nature of severe onychophagia: a comparison with self-cutting.

Wells JH, Haines J, Williams CL, Brain KL.

Can J Psychiatry. 1999 Feb;44(1):40-7.

PMID:
10076740
19.
20.

Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.

Dell'Osso B, Allen A, Hollander E.

Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. Review.

PMID:
16316311
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk